Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280549 | 0.87 | GRM2 (0.47) | GRM2SLC9A1TOP2AHCAR3 | |
| SCHEMBL5280496 | 0.84 | SLC9A1 (0.47) | GRM2SLC9A1TOP2AALDH1A1HCAR3 | |
| SCHEMBL5276690 | 0.81 | — | — | |
| SCHEMBL5280789 | 0.80 | GRM2 (0.43) | GRM2SLC9A1TOP2AALDH1A1ADORA2A | |
| SCHEMBL5280505 | 0.80 | GRM2 (0.43) | GRM2SLC9A1TOP2AALDH1A1ADORA2A | |
| SCHEMBL5279084 | 0.79 | GRM2 (0.40) | GRM2SLC9A1TOP2AALDH1A1ADORA2A | |
| SCHEMBL5285694 | 0.79 | GRM2 (0.40) | GRM2SLC9A1TOP2AALDH1A1GRIA4 | |
| SCHEMBL5274680 | 0.79 | GRM2 (0.40) | GRM2SLC9A1TOP2AALDH1A1ADORA2A | |
| SCHEMBL5277255 | 0.78 | GRM2 (0.42) | GRM2SLC9A1TOP2AALDH1A1GRIA4 | |
| SCHEMBL5285365 | 0.78 | GRM2 (0.42) | GRM2SLC9A1TOP2AALDH1A1GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-114728168-B | Triazole carbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114728168-A | Triazolecarbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021097039-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097039-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10487063-B2 | Preparation method for 1-substituted-1H-1,2,3-triazole 4-carboxylic acid | ABA CHEMICALS (SHANGHAI) LIMITED (CN) | 2019-11-26 | — | — | US | disclosed |
| US-20180029999-A1 | Preparation Method for 1-substituted-1H-1,2,3-triazole 4-carboxylic acid | ABA CHEMICALS (SHANGHAI) LIMITED (CN) | 2018-02-01 | — | — | US | disclosed |
| US-20180029999-A1 | Preparation Method for 1-substituted-1H-1,2,3-triazole 4-carboxylic acid | ABA CHEMICALS (SHANGHAI) LIMITED (CN) | 2018-02-01 | — | — | US | disclosed |
| WO-2013127028-A1 | PREPARATION METHOD FOR 1-SUBSTITUTED-4-BROMINE-1H-1,2,3-TRIAZOLE-5-CARBOXYLIC ACID | 苏州雅本化学股份有限公司 (CN) | 2013-09-06 | — | — | WO | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | GRM2 1914/4885SLC9A1 3696/4885TOP2A 4070/4885 |
| US-10487063-B2 | Preparation method for 1-substituted-1H-1,2,3-triazole 4-carboxylic acid | CLIC1, GRIK1, CA3 | GRM2 155/4885SLC9A1 595/4885TOP2A 1504/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | GRM2 1914/4885SLC9A1 3696/4885TOP2A 4070/4885 |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GRM2 1914/4885SLC9A1 3696/4885TOP2A 4070/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GRM2 1914/4885SLC9A1 3696/4885TOP2A 4070/4885 |
| US-20180029999-A1 | Preparation Method for 1-substituted-1H-1,2,3-triazole 4-carboxylic acid | CLIC1, GRIK1, CA3 | GRM2 155/4885SLC9A1 595/4885TOP2A 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.